Pfizer has begun providing Health Canada data on their new vaccine in hopes that it’s approved for use against new variants in the Fall.

“Today, Pfizer Canada and BioNTech filed a New Drug Submission (NDS) with Health Canada for an Omicron-adapted bivalent COVID-19 vaccine candidate, based on the BA.1 sub-lineage, to be administered as a booster dose in individuals 12 years of age and older,” writes Pfizer Canada.

However, unlike the original miracle vax, this vaccine doesn’t have the “safe and effective” label just yet.

“The safety and efficacy of this NDS is still under investigation, and market authorization has not yet been obtained,” Pfizer Canada writes. 

Meanwhile, the province of Manitoba has decided to delay its second booster vaccine campaign as they want to wait for new vaccines to be approved for the Fall — foreshadowing the inevitable approval of Pfizer’s vaccine and fresh mandates.

Last month, Pfizer CEO Albert Bourla said that “the beauty” of mRNA vaccines like Pfizer’s is that they can adapt every year to new variants, allowing for annual shots.

“I’m almost certain about it, and I say almost certain because, of course, regulators have the final say on all of that, but that’s the beauty of mRNA. You can adapt your vaccine just by changing the sequencing, which is a very minor change,” he said.

“For this reason, I’m very confident we will be able to respond very, very fast to every new variant.” 

Indeed, this new business model seems unfalsifiable, unlike their last – wherein their claim that vaccines were 97% effective at stopping symptomatic infection turned into “two doses of the vaccine offer very limited protection, if any.”

Now, with their updated annual subscription model, the absence of vaccine efficacy can be used as evidence that it’s time for a new vaccine. Thus, even if Pfizer’s vaccines wane, their stocks won’t go down as easily.